Week 14 serum infliximab trough levels in patients with and without sustained response to scheduled maintenance infliximab 5 and 10 mg/kg and with and without immunomodulator use
| Treatment | Patients with sustained response | Patients without sustained response | p Value* | All patients |
|---|---|---|---|---|
| Infliximab 5 mg/kg, all patients, n | 37 | 110 | 147 | |
| Median (IQR), μg/mL | 4.0 (1.7–6.8) | 1.9 (0.4–4.1) | 0.0331 | 2.2 (0.6–5.5) |
| Patients with immunomodulator use, n | 15 | 29 | 44 | |
| Median (IQR), μg/mL | 4.6 (2.7–10.6) | 1.7 (0.6–7.1) | 0.0047 | 2.7 (1.2–7.2) |
| Patients without immunomodulator use, n | 22 | 81 | 103 | |
| Median (IQR), μg/mL | 2.6 (0.7–6.8) | 2.0 (0.4–3.8) | 0.3134 | 2.2 (0.4–5.4) |
| Infliximab 10 mg/kg, all patients, n | 47 | 97 | 144 | |
| Median (IQR), μg/mL | 4.1 (1.7–7.1) | 1.9 (0.6–4.7) | 0.1109 | 2.4 (0.9–6.0) |
| Patients with immunomodulator use, n | 14 | 23 | 37 | |
| Median (IQR), μg/mL | 3.9 (0.9–5.8) | 2.7 (0.6–8.5) | 0.4263 | 3.1 (0.9–6.8) |
| Patients without immunomodulator use, n | 33 | 74 | 107 | |
| Median (IQR), μg/mL | 4.5 (1.8–7.2) | 1.8 (0.6–4.2) | 0.1278 | 2.2 (1.0–5.7) |
*p Value comparing patients with and without sustained response.